Back

Adverse cardiovascular events associated with kinase inhibitors and the prognostic value of imaging – a single-center retrospective cohort study in cancer patients

30 August 2026 (12:15 - 13:00)
Organised by: Logo
Congress Presentation Part of: Protection and safety in cardio‑oncology Cardiotoxicity of Drugs ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Jaiveer Singh

(United States of America)

5 More presentations in this session

Presentation thumbnail
Pleiotropic effects of canagliflozin and dapagliflozin in cadio-oncology: a novel strategy to balance antitumor efficacy and cardiotoxicity in HER2-positive breast cancer therapy
Doctor N. Maurea (Naples, IT)
Abstract
Presentation thumbnail
Febuxostat exacerbates doxorubicin-induced cardiac remodelling in a murine model of cardiomyopathy
Doctor S. Jezsoviczky (Budapest, HU)
Abstract
Presentation thumbnail
Genetic susceptibility to early anthracycline cardiotoxicity: the role of CBR3 polymorphisms
Miss A. Rozhanskiy (Sao Paulo, BR)
Abstract
Presentation thumbnail
Dynamic circulating microRNA signatures associated with cancer therapy-related cardiotoxicity in breast cancer patients
Doctor E. Oikonomou (Athens, GR)
Abstract
Presentation thumbnail
Sacubitril/valsartan and prevention of chemotherapy-induced cardiac dysfunction: meta-analysis of randomized trials
Doctor C. Fischer Bacca (Rio do Sul, BR)
Abstract

Access the full session

Session thumbnail
Protection and safety in cardio‑oncology

The Event

Event poster

ESC Congress 2026

30 August 2026 12:15 CET
You may be interested in
thumbnail
Congress Presentation
Adverse prognosis in cardio-oncology patients - who is guilty: the heart, the cancer or the patient?
29 June 2021
thumbnail
Congress Presentation
Direct effects of the tyrosine kinase inhibitors (TKIs) nilotinib and imatinib on the myocardium: clues towards cardiotoxic profiles
20 June 2025
thumbnail
Congress Presentation
Non-uniform cardiovascular risks of tyrosine kinase inhibitors associated with inhibition of C-terminal Src kinase
21 June 2025
thumbnail
Congress Presentation
Immune-related cardiovascular adverse events in a real-world cohort of patients treated with immune checkpoint inhibitors
20 June 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources